An interventional study of ERAS Perioperative Management Protocol in Peritoneal Carcinomatosis, sponsored by Fondazione del Piemonte per l'Oncologia. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Fondazione del Piemonte per l'Oncologia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Peritoneal Neoplasms with a site in Italy — 6 open to participants now, 8 under way, 3 of them phase 3. Peritoneal Neoplasms · Italy.
Among the 18 studies in Peritoneal Neoplasms with a site in Italy, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 with no phase, and was the 17th registered.
249 studies on the registry are indexed under Peritoneal Neoplasms; 54 are open to participants now.
Browse Peritoneal Neoplasms studies →6 of the 18 studies in Peritoneal Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Italy, United States, Australia and 24 more countries
Ages 18+
Corcept Therapeutics · Sites in Italy, United States, Belgium and 5 more countries
Ages 18+ · Women only
Oncoinvent Solutions AS · Sites in Italy, United States, Belgium and 3 more countries
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 48 Peritoneal Neoplasms studies recruiting now, 34 (71%) set no upper age limit and 8 (17%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 8
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 46 across 202 interventional studies indexed under Peritoneal Neoplasms.
Median enrollment 300 across the 15 interventional studies, 108 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
Fondazione del Piemonte per l'Oncologia is the lead sponsor of 39 studies on the registry; 18 are open to participants now.
Fondazione del Piemonte per l'Oncologia has 2 studies filed under Peritoneal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Peritoneal Neoplasms with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Peritoneal Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective multicenter interventional pre-post study aims to evaluate the effect of implementing an Enhanced Recovery After Surgery (ERAS) protocol in patients with peritoneal carcinomatosis undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC). Approximately 300 patients will be enrolled across 20 Italian centers. During an initial pre-intervention period, usual perioperative management will be described; during a subsequent intervention period, participating centers will apply a predefined ERAS protocol. The primary objective is to assess the effect of ERAS implementation on mean postoperative hospital length of stay.
Enhanced Recovery After Surgery (ERAS) is a multimodal perioperative care pathway designed to reduce surgical stress and accelerate postoperative recovery through coordinated evidence-based interventions involving surgery, anesthesia, nutrition, and rehabilitation. In patients with peritoneal carcinomatosis undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC), postoperative morbidity and prolonged hospitalization remain clinically relevant issues. This study will evaluate the implementation of a selected ERAS protocol in this setting. The study is designed as a multicenter interventional pre-post study: during the first period (approximately 4 months; 100 patients), usual perioperative procedures will be documented; during the second period (approximately 8 months; 200 patients), centers will apply a predefined ERAS pathway. Monitored ERAS elements include prehabilitation and preoperative counseling, nutritional assessment and support, bowel preparation and antibiotic prophylaxis, perioperative fasting management, postoperative oral intake, fluid management, and intra-/postoperative analgesic management.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants enrolled during the first study period (approximately 4 months; expected n=100) will undergo usual perioperative management for cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) as routinely practiced at each participating center.
Participants enrolled during the second study period (approximately 8 months; expected n=200) will undergo perioperative management according to a predefined Enhanced Recovery After Surgery (ERAS) protocol including preoperative counseling and prehabilitation, nutritional assessment and support, optimized fasting and carbohydrate loading, standardized antibiotic and antithrombotic prophylaxis, multimodal analgesia, goal-directed or restrictive fluid therapy, early oral intake, glycemic control, early mobilization, and discharge-readiness assessment.
Other: ERAS Perioperative Management Protocol
A multimodal perioperative care pathway for patients undergoing cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC), implemented by a multidisciplinary Enhanced Recovery After Surgery (ERAS) team and including coordinated preoperative, intraoperative, and postoperative measures aimed at reducing surgical stress and improving recovery.
Postoperative Hospital Length of Stay
Hospital length of stay measured in days from the date of surgery (Day 0) to the date of discharge from the index hospitalization. For the primary analysis, outliers with a hospital stay greater than the 95th percentile of the distribution will be excluded
Time frame: From Day 0 (date of surgery) to hospital discharge, assessed up to 90 days after surgery
Adherence to Selected ERAS Protocol Items
Adherence to the predefined ERAS perioperative items selected for monitoring, assessed across the preoperative, intraoperative, and postoperative phases of care
Time frame: Perioperative period, from preoperative assessment before surgery through hospital discharge during the index hospitalization, assessed up to 30 days after surgery
Incidence of Postoperative Complications
Incidence of postoperative complications defined according to the Clavien-Dindo classification.
Time frame: From the date of surgery to 30 days after surgery
Postoperative Intensive Care Unit Length of Stay
Length of postoperative intensive care unit (ICU) stay among participants admitted to the ICU after the index surgery, measured as the number of nights spent in intensive care
Time frame: From postoperative ICU admission after the index surgery to ICU discharge, assessed up to 30 days after surgery
Incidence of Reinterventions
Incidence of surgical reinterventions after the index procedure.
Time frame: From the date of surgery to 30 days after surgery
Incidence of Hospital Readmissions
Incidence of hospital readmissions after discharge following the index procedure.
Time frame: From hospital discharge to 30 days after surgery.
Incidence of Emergency Department Visits
Incidence of emergency department visits after the index procedure.
Time frame: From hospital discharge to 30 days after surgery.
Time to Recovery of Bowel Function
Time to recovery of bowel function, measured in days from the date of surgery to the first documented postoperative recovery of bowel function
Time frame: From Day 0 (date of surgery) to first documented recovery of bowel function, assessed daily during the index hospitalization, up to 30 days after surgery
All-Cause Mortality
Incidence of death from any cause.
Time frame: From the date of surgery to 30 days after surgery.
Quality of Postoperative Recovery
Mean quality of recovery score measured using the QoR-15 questionnaire.
Time frame: Approximately 48 hours after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jul 2026, 17 months after the start.
Of 34 interventional studies with no phase under Peritoneal Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 80. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione del Piemonte per l'Oncologia